Use of exogenous gangliosides as a protective factor against tox

Details Use of exogenous gangliosides as a protective factor against tox Use of exogenous gangliosides as a protective factor against tox

1987-06-25

1993-07-20

Brown, Johnnie R.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

514 54, 514283, 536 111, 536 53, 536 41, A61K 3170

Patent

active

052293734

ABSTRACT:
An agent for prevention or prophylaxis of general toxic effects or chronic neurotoxic effects which are caused by the administration of antineoplastic agents, which is to be given to patients prior to administration of said antineoplastic agents and which comprises as an active ingredient a mixture of gangliosides GM.sub.1, GD.sub.1a, GD.sub.1b and GT.sub.1b.

REFERENCES:
patent: 4728641 (1988-03-01), Jubaro et al.
Chemical Abstracts 107:126628g.
Chemical Abstracts 108:31499x.
Chemical Abstracts 108:197919j.
Leon et al., Membranes in Growth & Development, 311-320 (1982).
Brown et al., Ann. Rev. Neurosci. 4:17-42 (1981).
Toffano et al., Journal of Neurochemistry 35(4):861-866 (1980).
Aporti et al., Acta Otolaryngol 92:433-437 (1981).
Leon et al., Journal of Neurochemistry, 37(2):350-357 (1981).
Ledeen et al., Journal of Lipid Research, 9, 129-136 (1968).
Svennerholm et al., J. of Biological Chemistry, 248, #2, 740-742 (1973).
Svennerholm, Journal of Neurochemistry, 10, 613-623 (1963).
Fishman et al., Science, vol. 194, 906-915 (1976).
Gorio et al., Gangliosides in Neuro. & Neuromuscular Function, 177-195 (1981).
Gorio et al., Brain Research 197, 236-241 (1980).
Roisen et al., Science, 214, 577-578 (1981).
Hauw et al., C.R. Acad. Sc. Paris, t. 292, pp. 569-571 (1981).
Gorio et al., Birth Defects: Original Article Series, 19, #4, 157-174 (1983).
Norido et al., Experientia 37, pp. 301-302 (1981).
Norido et al., Muscle & Nerve, 5:107-110 (1982).
Maroni et al., Clinical Tosicology, 18(12), 1475-1484 (1981).
Ledeen, TINS, 169-174 (1985).
Hakomori, Ann. Rev. Biochem. 50:733-64 (1981).
Koulakoff et al., Developmental Biology 100, 350-357 (1983).
Willinger et al., Developmental Biology, 74, 101-117 (1980).
Hakomori, Biochimica et Biophysica Acta, 417, 55-89 (1975).
Hakamori, TIBS, Oct. 1984, 453-456.
Holland et al., Cancer Research, 33, 1258-1264 (1973).
Cho et al., Arch. Toxicol. 52:83-90 (1983).
Sato et al., Acta Neuropathol(Berl) 63:150-159 (1984).
McLeod et al., J. Neurol. Neurosurg. Psychiat., 32, 297-304 (1969).
Guiheneuc et al., Journal of Neurological Sciences, 45:355-366 (1980).
Gorio et al., Neuroscience, vol. 8, No. 3, 417-429 (1983).
The Lancet, FEb. 9, 1985, p. 346.
Dantona et al., International Symposium on Peripheral Neuropathies, RICERCA SCIENTIFICA ED EDUCAZIONE PERMANENTE, Suppl. 9, 155-158 (1978).
Azzoni, Il Policlinico-Sez. Medica, vol. 85, No. 4, pp. 1-8 (1978).
Aporti et al., Nuovo Archivio Italiano di Otologia, Rinologia e Laringologia, vol. V, pp. 25-31 (1977).

Affiliated with

Also associated with

Rating

Use of exogenous gangliosides as a protective factor against tox does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of exogenous gangliosides as a protective factor against tox, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of exogenous gangliosides as a protective factor against tox will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1760550